Our Science is Tailored Around the Patient
Acquired Resistance in Clinically Relevant Kinases
Acquired resistance with TKI therapy has been defined as disease progression after initial clinical benefit and can be attributed to selection of biological variants during TKI exposure. The development of next generation TKIs has proven to be very successful in mutant EGFR and ALK targeted therapies. Using our EPriL platform NTRC Therapeutics focuses on the discovery and development of next-generation kinase inhibitors to treat acquired drug resistance.